Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Uterine Cervical Neoplasms 1Papillomavirus Infections 1

Interventions

human papillomavirus vaccine, L1 type 16, 18 16Papillomavirus Vaccines 12Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 8Vaccines 5Human Papillomavirus DNA Tests 5Colposcopy 5Specimen Handling 4Blood Specimen Collection 4Watchful Waiting 3Vaginal Smears 3Patient Navigation 3Engerix-B 3Educational Status 3fludarabine phosphate 2fludarabine 2artesunic acid 2artemisinin 2aldesleukin 2Vaccines, Synthetic 2Standard of Care 2Practice Guidelines as Topic 2Polymerase Chain Reaction 2Mass Screening 2Light Coagulation 2Imiquimod 2Human Papillomavirus Recombinant Vaccine nonavalent 2GX-188 vaccine 2Early Intervention, Educational 2Data Collection 2Cyclophosphamide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Papillomavirus Infections × Chorionic Villi Sampling × Gynecologic × Clear all
NCT00947115 2020-10-30

Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects

GlaxoSmithKline

Phase 3 Completed
525 enrolled 24 charts
Gynecologic

Uterine Cervical Neoplasms, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡